News

Absorption Systems has introduced a renovated surgical suite for preclinical medical device testing at the company’s facility in San Diego, CA. The company’s AAALAC accredited, GLP-compliant facility is

Stentys has reported the first patient enrollment in the Apposition II clinical study, a randomised trial comparing the Stentys self-expanding stent with a balloon-expandable stent in AMI patients.

Oxygen Biotherapeutics (Oxygen) has reported the enrollment of first patient in the Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte emulsion in traumatic brain

Elan Drug Technologies, a business unit of Elan, has reported that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for Paliperidone Palmitate, aimed

The FDA has approved Santarus’s New Drug Application (NDA) for immediate-release Omeprazole/sodium bicarbonate/ magnesium hydroxide tablets in 40mg and 20mg dosage strengths of Omeprazole. Santarus had submitted the

Taro Pharmaceutical (Taro) has been granted an Investigational New Drug (IND) exemption by the FDA, to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). T2000 is one of a

Bristol-Myers Squibb and Pfizer are planning to submit an application for regulatory approval of Apixaban in Europe, for the prevention of venous thromboembolism (VTE) after orthopedic surgery, in

Galenea and Otsuka Pharmaceutical have reported the further extension of their research and development collaboration through 2011. The latest extension increases the collaboration term to seven years and

Dicerna Pharmaceuticals (Dicerna) and Kyowa Hakko Kirin have entered into a research collaboration and license agreement for the research, development and commercialisation of drug delivery systems and DsiRNA